Flunisyn, advanced development of a synthetic universal influenza T-cell vaccine
Dr Campbell Bunce, Research & Development Director, ITS Innovation
Despite significant leaps in Influenza treatment and prevention, there is still a significant unmet need. There is now heightened risk against new and more virulent influenza strains, as well as the continuing rish of pandemic remains, which a major threat to public health. Conventional influenza vaccines (TIVs) promote humoral immunity to influenza surface antigens (HA) and each year (irrespective of drift) New TIV has a risk of mismatch.
Statistics echo this opinion that needs are not being met. Protection across children and young adults is only around 60% and the elderly (>65 year olds) remain more at risk:
Â· Account for >90% of influenza-related deaths
Â· Efficacy of TIVs <40% in elderly – even with good vaccine match
Current forms of prevention are unable to manage new pandemic strain outbreaks.
The accumulating data supports the importance of cellular immunity (T cell responses) for influenza protection; especially T cell responses will be more effective in the protection of the elderly.
Dr Campbell Bunce, Research & Development Director, ITS Innovation joined us at the World Vaccine Congress Lyon, to give details on ITS Innovations' Flunisyn. To find out more, download the presentation here >
Please tell us what you think by commenting below.
Don't want to miss any of the presentations? Then subscribe here >